Trial Profile
An open label, 52 week clinical trial of glatiramer acetate in patients with relapsing-remitting multiple sclerosis in Japan
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Oct 2015
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors Teva Pharmaceutical Industries
- 28 Sep 2015 According to a Takeda media release, the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application for Glatiramer acetate (Copaxone) subcutaneous injection 20 mg syringe for the treatment of multiple sclerosis. The approval is based on the results of this and three other overseas clinical trials conducted by Teva in patients with relapsing- remitting multiple sclerosis.
- 30 Jul 2015 New trial record